Effects of colloidal bismuth subcitrate on aspirin-induced gastric microbleeding, DNA loss, and prostaglandin formation in humans.
Ten healthy young male subjects took part in a double-blind, placebo-controlled, crossover trial to assess the effect of colloidal bismuth subcitrate (De-No) on prostaglandin (PG) E2 generation and mucosal integrity in an aspirin (ASA)-treated stomach. After administration of ASA (2.5 g) plus placebo, a marked reduction in mucosal generation of PGE2 (by about 85%) was observed, and this was accompanied by a significant increase in gastric microbleeding and DNA loss and endoscopic and histologic damage of the mucosa. After the combination of De-Nol (300 mg four times daily) with ASA, mucosal generation of PGE2 showed a reduction similar to that in tests with ASA plus placebo, but gastric microbleeding and mucosal damage were significantly reduced. It is concluded that De-Nol has a protective action on ASA-induced gastric microbleeding and that this protection occurs despite a marked suppression of mucosal production of prostaglandins.
Konturek
S J
SJ
Institute of Physiology, Academy of Medicine, Cracow, Poland.
Kwiecień
N
N
Obtułowicz
W
W
Hebzda
Z
Z
Oleksy
J
J
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004247:DNA / Q000187:drug effects*; D015232:Dinoprostone / Q000096:biosynthesis*; D004311:Double-Blind Method; D005753:Gastric Mucosa / Q000378:metabolism; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011897:Random Allocation
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D004247:DNA; C002791:bismuth tripotassium dicitrate; D015232:Dinoprostone; D001241:Aspirin